Related Experiment Video

Updated: May 10, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

The molecular rationale of Src inhibition in colorectal carcinomas

Antonios N Gargalionis1, Michalis V Karamouzis, Athanasios G Papavassiliou

  • 1Molecular Oncology Unit, Department of Biological Chemistry, University of Athens Medical School, Athens, Greece.

International Journal of Cancer
|June 5, 2013
PubMed

Insights

Cellular Src (c-Src) is crucial in colorectal cancer (CRC) progression. Inhibiting c-Src shows promise in sensitizing tumors to chemotherapy and anti-EGFR therapies, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cellular Src (c-Src) is a proto-oncogene implicated in various human malignancies.
  • Activated c-Src is linked to aggressive colorectal cancer (CRC) phenotypes, poor prognosis, and enhanced tumor invasiveness and metastasis.
  • The interplay between c-Src activity and receptor tyrosine kinases (RTKs), like EGFR, is critical in CRC pathogenesis.

Purpose of the Study:

  • To explore the molecular mechanisms of c-Src inhibition in colorectal carcinomas.
  • To review preclinical and clinical studies on c-Src inhibitors and combination therapies.
  • To provide insights into novel therapeutic strategies for CRC.

Main Methods:

  • Literature review of molecular basis of c-Src inhibition.
  • Analysis of preclinical studies on c-Src inhibitors.
  • Examination of clinical trials involving c-Src inhibitors and combination regimens.

Main Results:

  • Deregulation of c-Src activity is strongly associated with CRC cell adhesion, invasiveness, and metastatic potential.
  • Src inhibition demonstrates potential to sensitize resistant cancer cells to chemotherapy and anti-EGFR therapies.
  • Targeting c-Src represents a promising therapeutic avenue for colorectal cancer.

Conclusions:

  • c-Src plays a pivotal role in colorectal cancer progression and metastasis.
  • Src inhibition offers a viable strategy to overcome therapeutic resistance in CRC.
  • Further investigation into c-Src inhibitors and combination therapies is warranted for developing new CRC treatment strategies.
Keywords:
Colorectal cancerEGFRSrcclinical trialtyrosine kinase

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...